Find Letermovir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Australia

Australia

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

93RELATED EXCIPIENT COMPANIES

136EXCIPIENTS BY APPLICATIONS

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 917389-32-3, Aic246, Prevymis, Aic-246, Aic 246, Mk-8228
Molecular Formula
C29H28F4N4O4
Molecular Weight
572.5  g/mol
InChI Key
FWYSMLBETOMXAG-QHCPKHFHSA-N
FDA UNII
1H09Y5WO1F

Letermovir
Letermovir is an orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.
Letermovir is a Cytomegalovirus DNA Terminase Complex Inhibitor. The mechanism of action of letermovir is as a DNA Terminase Complex Inhibitor, and Cytochrome P450 3A Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Cytochrome P450 2C8 Inhibitor, and Cytochrome P450 2C9 Inducer, and Cytochrome P450 2C19 Inducer.
1 2D Structure

Letermovir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetic acid
2.1.2 InChI
InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1
2.1.3 InChI Key
FWYSMLBETOMXAG-QHCPKHFHSA-N
2.1.4 Canonical SMILES
COC1=C(C=C(C=C1)C(F)(F)F)N2C(C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
2.1.5 Isomeric SMILES
COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
2.2 Other Identifiers
2.2.1 UNII
1H09Y5WO1F
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Aic246

2. Prevymis

2.3.2 Depositor-Supplied Synonyms

1. 917389-32-3

2. Aic246

3. Prevymis

4. Aic-246

5. Aic 246

6. Mk-8228

7. 1h09y5wo1f

8. 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetic Acid

9. 2-((4s)-8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-4h-quinazolin-4-yl)acetic Acid

10. 4-quinazolineacetic Acid, 8-fluoro-3,4-dihydro-2-(4-(3-methoxyphenyl)-1-piperazinyl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-, (4s)-

11. Letermovir [inn]

12. Letermovir [usan:inn]

13. Unii-1h09y5wo1f

14. Prevymis (tn)

15. (s)-[8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl]acetic Acid

16. (s)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazine-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazoline-4-yl}acetic Acid

17. Mk-8828

18. Letermovir(aic246)

19. Letermovir [mi]

20. Letermovir [jan]

21. Letermovir [usan]

22. Letermovir [who-dd]

23. Letermovir (jan/usan/inn)

24. Schembl379403

25. Chembl1241951

26. Letermovir [orange Book]

27. Dtxsid40238683

28. Ex-a1871

29. S8873

30. Zinc100369359

31. Cs-1571

32. Db12070

33. Aic246;aic 246;aic-246

34. Ncgc00378936-01

35. Ncgc00378936-02

36. Ac-35698

37. As-56206

38. Hy-15233

39. J3.556.145e

40. D10801

41. D71052

42. A902281

43. Q15409407

44. (4s)-2-(8-fluoro-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3-(2-methoxy-5-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-4-yl)acetic Acid

45. (4s)-8-fluoro-3,4-dihydro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4-quinazolineacetic Acid

46. (s)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydro-quinazolin-4-yl}acetic Acid

47. (s)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-(2-methoxy-5-trifluoromethylphenyl)-3,4-dihydroquinazolin-4-yl}acetic Acid

48. (s)-2-(8-fluoro-3-(2-methoxy-5-(trifluoromethyl)phenyl)-2-(4-(3-methoxyphenyl)piperazin-1-yl)-3,4-dihydroquinazolin-4-yl)acetic Acid

2.4 Create Date
2010-04-26
3 Chemical and Physical Properties
Molecular Weight 572.5 g/mol
Molecular Formula C29H28F4N4O4
XLogP34.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count10
Rotatable Bond Count7
Exact Mass572.20466804 g/mol
Monoisotopic Mass572.20466804 g/mol
Topological Polar Surface Area77.8 Ų
Heavy Atom Count41
Formal Charge0
Complexity931
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

For use in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).


FDA Label


Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).

Consideration should be given to official guidance on the appropriate use of antiviral agents.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Letermovir inhibits the activity of the DNA terminase complex of CMV thereby preventing the cutting of viral DNA into mature length genomes for packaging into viral particles. Letemovir inhibits the DNA terminase complex with an EC50 of 2.1nM.


5.2 MeSH Pharmacological Classification

Antiviral Agents

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)


Poly(ADP-ribose) Polymerase Inhibitors

Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES. (See all compounds classified as Poly(ADP-ribose) Polymerase Inhibitors.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
LETERMOVIR
5.3.2 FDA UNII
1H09Y5WO1F
5.3.3 Pharmacological Classes
Cytochrome P450 2C8 Inhibitors [MoA]; Cytochrome P450 2C9 Inducers [MoA]; Cytochrome P450 3A Inhibitors [MoA]; Cytomegalovirus DNA Terminase Complex Inhibitor [EPC]; DNA Terminase Complex Inhibitors [MoA]; Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]; Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]; Cytochrome P450 2C19 Inducers [MoA]
5.4 ATC Code

J05


J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AX - Other antivirals

J05AX18 - Letermovir


5.5 Absorption, Distribution and Excretion

Absorption

Letermovir has a bioavailability of 94% in healthy subjects when administered without cyclosporin, 35% in HSCT recipients when administered without cyclosporin, and 85% in HSCT recipients when administered with cyclosporin. Letermovir's Tmax is 45 min to 2.25 h. Time to steady state has been observed to be 9-10 days. Taking Letermovir with food increases Cmax by an average of 129.82% (range of 104.35%-161.50%). No significant effect on AUC has been observed .


Route of Elimination

Letemovir is taken up by the liver through OATP1B1/3 transporters. 93% is excreted in the feces with 70% as the parent drug. <2% is excreted in the urine.


Volume of Distribution

The mean steady state volume of distrubution is 45.5L


Clearance

The mean clearance is 11.25 L/h in healthy subjects


5.6 Metabolism/Metabolites

Letermovir undergoes a minor degree of metabolism through UGT1A1/1A3.


5.7 Biological Half-Life

The mean terminal half-life was observed to be 12 hours following administration of Letemovir 480 mg IV once daily.


5.8 Mechanism of Action

CMV relies on a DNA terminase complex consisting of multiple subunits (pUL51, pUL56, and pUL89) for processing of viral DNA. Viral DNA is produced in a single repeating strand which is then cut by the DNA terminase complex into individual viral genomes which can then be packaged into mature viral particles. Letemovir inhibits the activity of this complex to prevent production of mature viral genomes and the production of viable viral particles. The exact nature of Letemovir's binding to this complex is not currently known. Initially, the observation of resistance-causing mutations in pUL56 suggested this subunit was the location of Letemovir binding. However, resistance mutations have now been observed in pUL51, pUL56, and pUL89. It is possible that changes in amino acid sequence in one subunit could result in conformational changes to interacting subunits affecting Letemovir binding or that Letemovir interacts with multiple subunits of the complex but evidence towards either of these distinctions has not yet been seen. pUL89 is known to contain the endonuclease activity of the complex but because all members of the complex are necessary for targeting as well as protection from proteosomal degradation, it is difficult to discern if Letemovir inhibits pUL89's activity directly.


API SUPPLIERS

read-more
read-more

01

LEBSA

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLEBSA- Your strategic API source for niche molecules.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Lebsa Company Banner

02

Shandong Chenghui Shuangda Pharmac...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WCarrow-down NDC KDMF arrow-down VMF Others AUDIT
Shandong Chenghui Shuangda Pharmaceutical

03

Jinan Tantu Chemicals

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Jinan Tantu Chemicals

04

Honour Lab Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

05

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

06

TAPI Technology & API Services

Israel

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
TAPI Company Banner

07

Lupin Manufacturing Solutions

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Company Banner

08

Charioteer

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PREP
Not Confirmed
arrow

Charioteer

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PREP
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

Shanghai Desano Chemical Pharmaceu...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PREP
Not Confirmed
arrow

Shanghai Desano Chemical Pharmaceu...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PREP
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Nantong Jinghua Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

PREP
Not Confirmed
arrow

Nantong Jinghua Pharmaceutical

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
PREP
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 41441

Submission : 2025-06-29

Status : Active

Type : II

Company Banner

02

PREP
Not Confirmed

03

PREP
Not Confirmed

03

PREP
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-07-06

Pay. Date : 2021-06-16

DMF Number : 35981

Submission : 2021-06-10

Status : Active

Type : II

blank

04

PREP
Not Confirmed

05

PREP
Not Confirmed

06

PREP
Not Confirmed

06

PREP
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-09-29

Pay. Date : 2021-09-17

DMF Number : 36024

Submission : 2021-06-19

Status : Active

Type : II

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-moreread-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.

Flag China
Digital Content Digital Content

Letermovir

Date of Issue : 2024-08-28

Valid Till : 2027-08-27

Written Confirmation Number : SD240048

Address of the Firm : Economic Development Zone, Pingyuan County, Dezhou City, Shandong

Shandong Chenghui Shuangda Pharmaceutical
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

LEBSA

Spain
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLEBSA- Your strategic API source for niche molecules.

Flag Spain
Digital Content Digital Content

Letermovir

About the Company : Lebsa is an innovative European laboratory that specializes in the synthesis, manufacture and commercialization of APIs with a focus on niche products. With a track record spanning...

Lebsa is an innovative European laboratory that specializes in the synthesis, manufacture and commercialization of APIs with a focus on niche products. With a track record spanning 70 years, Lebsa has established itself as a reputable player in the global pharmaceutical market, particularly in generic API manufacturing. Headquartered in Barcelona, Spain, Lebsa exports up to 90% of its production. Lebsa's state-of-the-art facilities, located near Barcelona, feature cutting-edge technology, equipment and automated processes. Lebsa has expertise in registering APIs in countries across Europe, Canada, Taiwan, China, Russia, Brazil and Japan.
Lebsa Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChina's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.

Flag China
Digital Content Digital Content

Letermovir

About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer of Finished Formulat...

Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. specializes in R&D and production of APIs and advanced intermediates, CDMO/CRO/OEM, and Technology Transfer of Finished Formulations. With 23 years of production experience, the company operates 6 GMP-compliant workshops, achieving a monthly capacity of 100 tons to meet cGMP requirements. Currently, the factory has registered 21 APIs in NMPA, filed 4 US-DMFs, and applied for 9 CEPs, while successfully passing audits by MFDS, US FDA, and global customers.
Shandong Chenghui Shuangda Pharmaceutical

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

Flag China
Digital Content Digital Content

Letermovir

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include customized R&D as well as the production of small molecule pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) for both international and domestic pharmaceutical firms. Our capabilities span from laboratory-scale kilograms to commercial ton-scale production. Additionally, we are committed to independent research and development, as well as the production and sales of high-end pharmaceutical intermediates and API products.
Jinan Tantu Chemicals

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHonour is a leading global CDMO and specialty chemicals manufacturer with seven world-class sites delivering quality-driven solutions.

Flag India
Digital Content Digital Content

Letermovir

About the Company : Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standar...

Honour is a leading global CDMO and a trusted manufacturer of specialty chemicals and ingredients. With seven world-class facilities built to meet global safety and quality standards, we are committed to delivering excellence with innovative, holistic solutions to clients across the globe by leveraging our expertise in chemistry. Operating through our two core verticals - Honour Synthesis and Honour Specialty, we embrace the science of partnership and possibilities. Our team of over 2,500 professionals collaborates closely with pharmaceutical, biotechnology, and specialty industries worldwide to develop practical, scalable solutions.
Company Banner

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Letermovir

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Letermovir

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

Flag India
Digital Content Digital Content

Letermovir

About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...

Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of pharma expertise, LMS combines cost efficiency with regulatory excellence. With world-class sites in Dabhasa and Vizag, and an R&D center in Pune, we deliver integrated, sustainable, and globally compliant solutions that accelerate drug development and reduce environmental impact.
Company Banner

08

Organic Process R&D
Not Confirmed
arrow
arrow
Organic Process R&D
Not Confirmed

Letermovir

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

09

Organic Process R&D
Not Confirmed
arrow
arrow
Organic Process R&D
Not Confirmed

Letermovir

About the Company : Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Ant...

Globe Quimica S.A. is a major Brazilian API producer, GMP certificated by ANVISA, manufactures more than 20 different API's such as Antiretrovirals, Anxiolytic, Antidepressant, Antithrombotic, Analgesic. In 2012 Globe Quimica has started-up its new API plant for Active Ingredients for Oncologic Drugs.
blank

10

Organic Process R&D
Not Confirmed
arrow
arrow
Organic Process R&D
Not Confirmed

Letermovir

About the Company : Nantong Jinghua Pharmaceutical is a public pharmaceutical company that was established in 1957, owns about 302 staff, located in No. 20, 3 Haibin Road, Yanhai Economic Development ...

Nantong Jinghua Pharmaceutical is a public pharmaceutical company that was established in 1957, owns about 302 staff, located in No. 20, 3 Haibin Road, Yanhai Economic Development Zone, Rudong, Nantong, Jiangsu, China. They are appointed as a high-new-technical enterprise by Jiangsu Scientific Technological Bureau. As a comprehensive, advanced, and innovative GMP company, they focus on the manufacture, R&D, and sales of APIs and pharmaceutical intermediates. The Company produces Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Flucytosine, Piroxicam, Propylthiouracil, etc., in which the first five products have CEP certificates.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690828200,"product":"LETERMOVIR","address":"NA","city":"AHMEDABAD","supplier":"CADILA HEALTHCARE LTD","supplierCountry":"INDIA","foreign_port":"REYKJAVIK","customer":"CORIPHARMA EHF","customerCountry":"ICELAND","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"20000","totalValueFC":"21739.4","currency":"EURO","unitRateINR":1800813.9240000001,"date":"01-Aug-2023","totalValueINR":"1800813.924","totalValueInUsd":"21739.4","indian_port":"BOMBAY AIR","hs_no":"29335990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"ICELAND","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NA, AHMEDABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705602600,"product":"BULK DRUG : LETERMOVIR","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"LUPIN LTD","supplierCountry":"INDIA","foreign_port":"SHANGHAI - PU DONG","customer":"GREENPINE PHARMA GROUP CO LTD","customerCountry":"CHINA","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"16000","totalValueFC":"7850.1","currency":"USD","unitRateINR":1304874,"date":"19-Jan-2024","totalValueINR":"652437","totalValueInUsd":"7850.1","indian_port":"Bombay Air","hs_no":"29420090","bill_no":"6864583","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"159, C.S.T. ROAD,, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1711391400,"product":"LETERMOVIR","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"WORLD MEDICINE ILAC SAN VE TIC AS","customerCountry":"TURKEY","quantity":"3.00","actualQuantity":"3","unit":"KGS","unitRateFc":"13000","totalValueFC":"38330.8","currency":"USD","unitRateINR":1060943.3333333333,"date":"26-Mar-2024","totalValueINR":"3182830","totalValueInUsd":"38330.8","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"8617028","productDescription":"API","marketType":"","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1738175400,"product":"LETERMOVIR B\/N- KLLTR24001","address":"159, C.S.T. ROAD,","city":"MUMBAI,MAHARASHTRA","supplier":"LUPIN LTD","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"APOTEX INC SIGNET","customerCountry":"CANADA","quantity":"2.00","actualQuantity":"2","unit":"KGS","unitRateFc":"10000","totalValueFC":"19680.9","currency":"USD","unitRateINR":848534.40000000002,"date":"30-Jan-2025","totalValueINR":"1697068.8","totalValueInUsd":"19680.9","indian_port":"Bombay Air","hs_no":"29420013","bill_no":"7718346","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"159, C.S.T. ROAD,, MUMBAI,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1743013800,"product":"LETERMOVIR","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR","city":"AHMEDABAD\/GUJRAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"RIYADH","customer":"SAUDI PHARMACEUTICAL INDUSTRIES","customerCountry":"SAUDI ARABIA","quantity":"30.44","actualQuantity":"30.435","unit":"KGS","unitRateFc":"8150","totalValueFC":"244726","currency":"USD","unitRateINR":696486.85395104322,"date":"27-Mar-2025","totalValueINR":"21197577.4","totalValueInUsd":"244726","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"9395014","productDescription":"API","marketType":"","country":"SAUDI ARABIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR, AHMEDABAD\/GUJRAT","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729881000,"product":"LETERMOVIR","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"SHANGHAI LIGHT INDUSTRIAL PRODUCTS","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"ALEMBIC PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"9600","totalValueFC":"2426.4","currency":"USD","unitRateINR":"815520","date":"26-Oct-2024","totalValueINR":"203880","totalValueInUsd":"2426.4","indian_port":"Bombay Air","hs_no":"29335990","bill_no":"6357055","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"SUNRISE) IMP. & EXP. CORP.LTDRM1002 , BLD.A, NO.1230,ZHONG SHAN (NORTH 1) RD,SHANGHAI 200437 CHINA","customerAddress":"ALEMBIC ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1731868200,"product":"LETERMOVIR GUANIDINE SALICYLATE INTERMEDIATE\/SYMMETRICAL ACRYLATE GUANIDINE RT.(FREE OF COST VALUE FOR CUSTOMS PURPOSES","address":"7.1.77\/E\/1\/303, DHARAM KARAM ROAD","city":"HYDERABAD,A.P.","supplier":"XXRCKXXHARXX DXXME XXC","supplierCountry":"SWITZERLAND","foreign_port":"NEW YORK","customer":"DIVIS LABORATORIES LTDDSN SEZ UNIT","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"10","unit":"GMS","unitRateFc":"12.5","totalValueFC":"126.8","currency":"USD","unitRateINR":"1069.7","date":"18-Nov-2024","totalValueINR":"10697","totalValueInUsd":"126.8","indian_port":"Vizag-DLL SEZ","hs_no":"29335990","bill_no":"1000958","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"NEW YORK","supplierAddress":"N\/A","customerAddress":"7.1.77\/E\/1\/303, DHARAM KARAM ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q2","strtotime":1746729000,"product":"LETERMOVIR CAS:917389-32-3 LETERMOVIR CAS:917389-32-3","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"SHANGHAI LIGHT INDUSTRIAL PRODUCTS SUNRISE IMP","supplierCountry":"CHINA","foreign_port":"SHANGHAI","customer":"ALEMBIC PHARMACEUTICALS LTD","customerCountry":"INDIA","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"6100","totalValueFC":"30625.1","currency":"USD","unitRateINR":"521855","date":"09-May-2025","totalValueINR":"2609275","totalValueInUsd":"30625.1","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"9966446","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"SHANGHAI","supplierAddress":"EXP. CORP., LTD. Rm1002,Bld. A, 1230, Zhong Shan (North 1) Rd, Shanghai 200437 CHINA","customerAddress":"ALEMBIC ROAD"},{"dataSource":"API Import","activeIngredients":"","year":"2025","qtr":"Q3","strtotime":1753209000,"product":"LETERMOVIR GUANIDINE SALICYLATE INTERMEDIATE\/ SYMMETRICALACRYLATE GUANIDINE RT","address":"7.1.77\/E\/1\/303, DHARAM KARAM ROAD","city":"HYDERABAD,A.P.","supplier":"MERCK SHARP DOHME LLC","supplierCountry":"SWITZERLAND","foreign_port":"NEW YORK","customer":"DIVIS LABORATORIES LTD","customerCountry":"INDIA","quantity":"0.01","actualQuantity":"5","unit":"GMS","unitRateFc":"12.5","totalValueFC":"63.2","currency":"USD","unitRateINR":"1088.5","date":"23-Jul-2025","totalValueINR":"5442.36","totalValueInUsd":"63.2","indian_port":"Vizag-DLL SEZ","hs_no":"29335990","bill_no":"3436574","productDescription":"Intermediate","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"NEW YORK","supplierAddress":"126 E.LINCOLN AVENUE RAHWAY,NJ SDNF UNITED STATES","customerAddress":"7.1.77\/E\/1\/303, DHARAM KARAM ROAD"}]
01-Aug-2023
23-Jul-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Failure, Chronic.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Nephrology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Jason A Roberts | Royal Brisbane and Women's Hospital

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 03, 2025

blank

01

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Lead Product(s) : Letermovir,Inapplicable

Therapeutic Area : Nephrology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Jason A Roberts | Royal Brisbane and Women's Hospital

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Failure, Chronic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 03, 2025

blank

Details:

Anvimo (letermovir), is CMV DNA terminase inhibitor small molecule drug candidate, which is indicated for the treatment of cytomegalovirus infection.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Anvimo

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 06, 2025

blank

02

PREP
Not Confirmed
PREP
Not Confirmed

Details : Anvimo (letermovir), is CMV DNA terminase inhibitor small molecule drug candidate, which is indicated for the treatment of cytomegalovirus infection.

Product Name : Anvimo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 06, 2025

blank
  • Development Update

Details:

Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 09, 2024

blank

03

University of Wisconsin, Madison

Country
arrow
PackExpo
Not Confirmed

University of Wisconsin, Madison

Country
arrow
PackExpo
Not Confirmed

Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 09, 2024

blank

Details:

Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.


Lead Product(s): Letermovir,Acyclovir

Therapeutic Area: Infections and Infectious Diseases Brand Name: Prevymis

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable April 19, 2024

blank

04

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Details : Prevymis (letermovir) is a CMV DNA terminase complex inhibitor small molecule drug candidate, which is indicated for cytomegalovirus disease in high-risk adult kidney transplant recipients.

Product Name : Prevymis

Product Type : Miscellaneous

Upfront Cash : Inapplicable

April 19, 2024

blank

Details:

Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Prevymis

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 17, 2023

blank

05

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex, which is indicated for the treatment of Cytomegalovirus.

Product Name : Prevymis

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 17, 2023

blank
  • Development Update

Details:

Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 04, 2023

blank

06

University of Pennsylvania

Country
arrow
PackExpo
Not Confirmed

University of Pennsylvania

Country
arrow
PackExpo
Not Confirmed

Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 04, 2023

blank
  • Development Update

Details:

Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 28, 2023

blank

07

Maimónides Biomedical Research Institute of Córdoba

Country
arrow
PackExpo
Not Confirmed

Maimónides Biomedical Research Institute of Córdoba

Country
arrow
PackExpo
Not Confirmed

Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 28, 2023

blank
  • Development Update

Details:

Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Immunology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Merck & Co

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable August 21, 2023

blank

08

Virginia Commonwealth University

Country
arrow
PackExpo
Not Confirmed

Virginia Commonwealth University

Country
arrow
PackExpo
Not Confirmed

Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft Rejection.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

August 21, 2023

blank

Details:

Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Prevymis

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 06, 2023

blank

09

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Details : Prevymis (letermovir) is a first-in-class non-nucleoside CMV inhibitor (3,4 dihydro-quinazolines) and inhibits viral replication by specifically targeting the viral terminase complex and FDA Approves New Indication forCytomegalovirus.

Product Name : Prevymis

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 06, 2023

blank

Details:

Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.


Lead Product(s): Letermovir,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2023

blank

10

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Merck & Co

U.S.A
arrow
PackExpo
Not Confirmed

Details : Letermovir is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cytomegalovirus Infections.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 10, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Granulation

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Coating Systems & Additives

read-more
read-more

Parenteral

read-more
read-more

Taste Masking

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Solubilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 917389-32-3 / Letermovir API manufacturers, exporters & distributors?

Letermovir manufacturers, exporters & distributors 1

72

PharmaCompass offers a list of Letermovir API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Letermovir manufacturer or Letermovir supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Letermovir manufacturer or Letermovir supplier.

PharmaCompass also assists you with knowing the Letermovir API Price utilized in the formulation of products. Letermovir API Price is not always fixed or binding as the Letermovir Price is obtained through a variety of data sources. The Letermovir Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Letermovir

Synonyms

917389-32-3, Aic246, Prevymis, Aic-246, Aic 246, Mk-8228

Cas Number

917389-32-3

Unique Ingredient Identifier (UNII)

1H09Y5WO1F

About Letermovir

Letermovir is an orally bioavailable, non-nucleoside, 3,4-dihydroquinazolinyl acetic acid and inhibitor of the pUL56 subunit of the viral terminase complex of cytomegalovirus (CMV), with potential CMV-specific antiviral activity. Upon oral administration, letermovir binds to the pUL56 subunit of the viral terminase complex of CMV and prevents the cleavage of concatemeric DNA into monomeric genome length DNA. As this agent interferes with viral DNA processing and subsequent viral DNA packaging into procapsids, CMV replication is blocked and CMV infection is prevented.

Letermovir Manufacturers

A Letermovir manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Letermovir, including repackagers and relabelers. The FDA regulates Letermovir manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Letermovir API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Letermovir manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Letermovir Suppliers

A Letermovir supplier is an individual or a company that provides Letermovir active pharmaceutical ingredient (API) or Letermovir finished formulations upon request. The Letermovir suppliers may include Letermovir API manufacturers, exporters, distributors and traders.

click here to find a list of Letermovir suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Letermovir USDMF

A Letermovir DMF (Drug Master File) is a document detailing the whole manufacturing process of Letermovir active pharmaceutical ingredient (API) in detail. Different forms of Letermovir DMFs exist exist since differing nations have different regulations, such as Letermovir USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Letermovir DMF submitted to regulatory agencies in the US is known as a USDMF. Letermovir USDMF includes data on Letermovir's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Letermovir USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Letermovir suppliers with USDMF on PharmaCompass.

Letermovir KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Letermovir Drug Master File in Korea (Letermovir KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Letermovir. The MFDS reviews the Letermovir KDMF as part of the drug registration process and uses the information provided in the Letermovir KDMF to evaluate the safety and efficacy of the drug.

After submitting a Letermovir KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Letermovir API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Letermovir suppliers with KDMF on PharmaCompass.

Letermovir WC

A Letermovir written confirmation (Letermovir WC) is an official document issued by a regulatory agency to a Letermovir manufacturer, verifying that the manufacturing facility of a Letermovir active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Letermovir APIs or Letermovir finished pharmaceutical products to another nation, regulatory agencies frequently require a Letermovir WC (written confirmation) as part of the regulatory process.

click here to find a list of Letermovir suppliers with Written Confirmation (WC) on PharmaCompass.

Letermovir NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Letermovir as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Letermovir API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Letermovir as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Letermovir and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Letermovir NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Letermovir suppliers with NDC on PharmaCompass.

Letermovir GMP

Letermovir Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Letermovir GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Letermovir GMP manufacturer or Letermovir GMP API supplier for your needs.

Letermovir CoA

A Letermovir CoA (Certificate of Analysis) is a formal document that attests to Letermovir's compliance with Letermovir specifications and serves as a tool for batch-level quality control.

Letermovir CoA mostly includes findings from lab analyses of a specific batch. For each Letermovir CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Letermovir may be tested according to a variety of international standards, such as European Pharmacopoeia (Letermovir EP), Letermovir JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Letermovir USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty